Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine - Wikidata - awgldk - TriplyDB

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

http://www.wikidata.org/entity/Q24685403

about

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis Vedolizumab for the treatment of ulcerative colitis and Crohn's disease Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease Cancer in inflammatory bowel disease Risks and benefits of azathioprine therapy Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders Therapy of NMO spectrum disorders Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease Use of thiopurines in inflammatory bowel disease Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease Review article: anti-adhesion therapies for inflammatory bowel disease Use of the tumor necrosis factor-blockers for Crohn's disease Optimizing the use of thiopurines in inflammatory bowel disease Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease.Gamma-delta t-cell lymphomas.Combination therapy for inflammatory bowel disease Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.Anaplastic large cell lymphoma of the colon in a patient with colonic Crohn disease treated with infliximab and methotrexate.Radiation exposure from abdominal imaging studies in patients with intestinal Behçet disease.Summary of worldwide pediatric malignancies reported after exposure to etanercept.Emerging data in the concomitant use of immunomodulators and biologic therapies.Patient preferences for surgical versus medical therapy for ulcerative colitis.Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry.Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.Thiopurine methyltransferase predicts the extent of cytotoxicty and DNA damage in astroglial cells after thioguanine exposure.Current status of thiopurine analogues in the treatment in Crohn's disease.Enteral nutrition in Crohn's disease: an underused therapy.Tailoring the treatment to the individual in Crohn's disease.

P2860

Q24186291-0A60FEF9-6514-49E9-849F-B477FF38A94D Q24200184-BD830676-FC07-4D2B-B819-43868AC00394 Q24200757-FC4A5347-9C5B-4A72-93A7-DC5731DC0B6E Q24241348-91A5A933-68A4-40BD-97FF-551F56AAC5C6 Q24243219-D71C926A-CC47-4658-BD22-C58B532DC1B0 Q24244006-724573C8-A399-4819-932B-B449525658F9 Q24630083-B686F6E2-4564-45A4-B2BF-4EF03E2AA920 Q24631869-0A7755A1-B5B6-45F6-B312-1E049B42696C Q24648315-AF508075-8B5B-4DC9-BB72-B76C467D2204 Q24685436-C79473B4-BEB5-4F3D-AC4E-9B390ED9E1ED Q26739361-9DC25DB8-C2C2-412E-AE5B-8257EB1BF9B5 Q26768280-8227AA16-5CB5-4E65-A0D9-233D5029A81F Q26776151-C49ECE21-B07D-4DAA-A04A-24925C7C956D Q26779910-2281E4B0-593F-4C0F-BF1B-C2A2C25D0A55 Q26801119-53704BD3-7AC0-4549-9BC9-797DCE5B3883 Q26822029-022A6C01-4252-4DE0-BE0F-59D43670E3C5 Q26824662-7B1E2323-E903-4C57-A0D9-212C762387D8 Q26826827-C59AF978-5110-460C-BEA3-D4E8ADE87756 Q26864906-E030357B-F06B-4B74-A2ED-900783AE4C73 Q26866940-A9FE6380-DF37-4CE4-8419-D729FB9C20F8 Q26999705-65B48A28-152D-44EA-A7C5-DBB8D69390DC Q27030762-FDACA944-577E-4160-8C4A-31AEBEC44DC6 Q28082687-C62DE942-23A6-4725-85BB-F37C997BBEA8 Q28243814-FAB4C146-6AE1-4DF4-9865-BECD7B0E4069 Q33268021-658EDBC7-69CE-4026-AD18-6449F8B77D64 Q33417290-82FF8C9C-B51E-4D4A-9EEE-EE45301DEEEF Q33646452-A218D112-375B-441C-ACF0-665EB949C125 Q33750759-60923F29-D375-49ED-BD7B-3E5B975CB169 Q33756929-98E9AA78-D496-4168-9CD3-E3CAA6687709 Q33810149-7F9FB73F-EA47-4423-B17C-29DEB477F910 Q33959688-5F40C41D-AAB6-487A-A552-5FAE4410D151 Q33998050-600A26D6-9539-4620-8C25-520BD6668379 Q34035727-16666CD1-6160-4F32-989A-1AFE24BCEE45 Q34065549-6F4F1A44-1A3E-4D44-81FF-BA590003546F Q34077378-7474C887-958C-46C6-84FF-D62AB904E2D1 Q34078707-F5F284E8-CF8D-43CB-9241-7FBE84EB6A4A Q34117269-0316C3D8-27A6-483E-8FA9-248863B7600A Q34235370-19189C93-B1B8-4D47-BAE8-A4D2680351E2 Q34395233-1C2D7B77-426A-43A5-9493-77AF301DA762 Q34409001-CEE1B177-1DBD-4373-9661-19E2941DBEC1

P2860

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

http://www.wikidata.org/entity/Q24685403

description

2005 nî lūn-bûn

@nan

2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Increased risk of lymphoma amo ...... thioprine and 6-mercaptopurine

@ast

Increased risk of lymphoma amo ...... thioprine and 6-mercaptopurine

@en

Increased risk of lymphoma amo ...... thioprine and 6-mercaptopurine

@nl

type

label

Increased risk of lymphoma amo ...... thioprine and 6-mercaptopurine

@ast

Increased risk of lymphoma amo ...... thioprine and 6-mercaptopurine

@en

Increased risk of lymphoma amo ...... thioprine and 6-mercaptopurine

@nl

prefLabel

Increased risk of lymphoma amo ...... thioprine and 6-mercaptopurine

@ast

Increased risk of lymphoma amo ...... thioprine and 6-mercaptopurine

@en

Increased risk of lymphoma amo ...... thioprine and 6-mercaptopurine

@nl

P1433

Q24685403-966BB871-DCAD-4F64-B330-F4A40EBD46EF

P1476

Q24685403-8F12288F-5A8F-473F-B461-425D078419B7

P2093

Q24685403-0B8747E8-40A4-4079-8156-0B2EDBCE391A

Q24685403-210A68BB-29D7-45C1-A463-623C15A9A0DD

Q24685403-4809CDC1-9596-4F4E-96E3-A326A2AED52B

Q24685403-D5F2E31C-BCFB-4AE1-A4ED-A0CF1F57F045

Q24685403-DC9C2950-BE9D-4E20-BA85-A36AC7829772

P2860

Q24685403-1D1F0DDB-065B-4635-B0AE-A23BA57D418C

Q24685403-3E8AEAE3-36A9-498D-A6A9-E1CA102A3DD7

Q24685403-58A481D3-B4F1-4003-857C-54CD3EDEDA76

Q24685403-58CA1E1F-52CE-4210-A698-8F7AFB3082C2

Q24685403-5BEAED2B-1746-4D96-AE00-80FE9B9D160C

Q24685403-872157C8-80C5-4B19-83CB-6A7F0A397703

Q24685403-879ADC76-86F5-4533-8046-1C69C3F59ADF

Q24685403-91F0E66A-762A-4980-8892-52CDD2574682

Q24685403-BD0E30D0-784E-45B0-91F3-1B8899EF66CB

Q24685403-C253A6C6-B9CD-4FCC-9248-20AAABC864B0

P304

Q24685403-7D1C8FED-70F3-43DB-B547-376D36000CC2

P31

Q24685403-0fdfc4ea-083e-466e-b858-aac91397f403

Q24685403-11E9A1CB-597B-4F42-8D24-08AC61458833

P3181

Q24685403-7E31302E-1903-4442-A552-125DCC76218D

P356

Q24685403-96F57B36-32CE-44AC-820F-7C67BBFB514F

P407

Q24685403-FB2B0A59-E9DF-4356-9A8D-F17161456784

P433

Q24685403-BC16DBA5-A41E-4066-B959-6A269C0A716C

P478

Q24685403-6DB79F05-A894-44A8-B1E6-592AB61C272E

P577

Q24685403-BAF721C1-ECBB-457C-9A78-D4E51F061BF7

P5875

Q24685403-A9C20793-CB6A-4F98-ABA7-63EDCF85A316

P698

Q24685403-3F946E0B-F0E6-4888-A42A-094D3AFFA725

P921

Q24685403-4EEF54C9-F715-4B87-88A7-0D649F0371BC

Q24685403-6569B9A5-FB55-4EE8-8BBA-CA1A30B057FF

Q24685403-ACB83994-BBBF-4CEA-A71A-8099DBE93843

Q24685403-C1970122-03B7-48F2-86A7-E2E713164D4D

P932

Q24685403-EADC64EF-0ACE-4458-A395-6D93D4F335E6

P3181

P356

GUT.2004.049460

P1433

P1476

Increased risk of lymphoma amo ...... thioprine and 6-mercaptopurine

@en

P2093

A G Fraser

http://www.w3.org/2001/XMLSchema#string

A Kandiel

http://www.w3.org/2001/XMLSchema#string

B I Korelitz

http://www.w3.org/2001/XMLSchema#string

C Brensinger

http://www.w3.org/2001/XMLSchema#string

J D Lewis

http://www.w3.org/2001/XMLSchema#string

P2860

Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study

Azathioprine: state of the art in inflammatory bowel disease.

Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine.

Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low

Risk of lymphoma in inflammatory bowel disease.

Increased risk of cancer in ulcerative colitis: a population-based cohort study.

Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.

Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment.

Extracolonic malignancies in inflammatory bowel disease.

Hodgkin's disease risk is increased in patients with ulcerative colitis.

P304

1121-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

472876

http://www.w3.org/2001/XMLSchema#string

P356

10.1136/GUT.2004.049460

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7734283

http://www.w3.org/2001/XMLSchema#string

P698

16009685

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases

P932

1774897

http://www.w3.org/2001/XMLSchema#string